Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors

<b>Background/Objectives:</b> The dual targeting of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) represents an effective approach for cancer treatment. The current study involved the design, synthesis, and biological evaluation of a new seri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Fatemah S. Albalawi, Mashooq A. Bhat, Ahmed H. Bakheit, A. F. M. Motiur Rahman, Nawaf A. Alsaif, Alan M. Jones, Isolda Romero-Canelon
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Pharmaceuticals
Subjects:	cancer EGFR HER2 EGFR- and HER2-driven cancers purine/hydrazone-containing compounds lapatinib
Online Access:	https://www.mdpi.com/1424-8247/18/7/1051
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Molecular Docking and Pharmacological In Silico Evaluation of Camptothecin and Related Ligands as Promising HER2-Targeted Therapies for Breast Cancer
by: Elmer Joel Millan-Casarrubias, et al.
Published: (2025-03-01)

Improving treatment outcomes for patients with HER2‑positive breast cancer using neoadjuvant double HER2 blockade
by: V. F. Semiglazov, et al.
Published: (2024-11-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)

Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01)

Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01)

Fully automatic HER2 tissue segmentation for interpretable HER2 scoring
by: Mathias Öttl, et al.
Published: (2025-04-01)

The effectiveness of three months EGFR-CTH therapy in palliative colorectal cancer
by: Maciej Pawel Jankowski, et al.
Published: (2025-01-01)

Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study
by: Lei Zhou, et al.
Published: (2025-07-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Concordance of HER2-low scoring in breast carcinomas among pathologists
by: Snježana Tomić, et al.
Published: (2025-07-01)

HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) IN GASTRIC CANCER (GC) (RESULTS OF THE MULTICENTER CLINICAL TRIAL)
by: H. C. Chung, et al.
Published: (2017-02-01)

Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors
by: Kristian Egebjerg, et al.
Published: (2025-08-01)

STUDY OF THE EFFECT OF LOMUSTIN ON HER2-POSITIVE BREAST CANCER IN FVB/N HER-2 TRANSGENIC MICE
by: A. N. Stukov, et al.
Published: (2019-11-01)

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER
by: O. I. Kit, et al.
Published: (2021-05-01)

New benzimidazole-triazole glycoconjugates as anti-cancer agents and EGFR inhibitors
by: Aladdin M. Srour, et al.
Published: (2025-07-01)

CLINICAL CHARACTERISTICS OF BREAST CANCER WITH STEROID RECEPTORS EXPRESSION AND HER2 AMPLIFICATION
by: F. V. Moiseenko, et al.
Published: (2017-02-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression
by: Chunbo He, et al.
Published: (2015-09-01)

Detection of EGFR gene mutations for prescription of targeted drugs for non-small cell lung cancer
by: O. N. Pavlova, et al.
Published: (2024-04-01)

Molecular targets for metastasis-directed therapy in malignant tumors
by: V. V. Bodenko, et al.
Published: (2024-07-01)

High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study
by: Yin Pan, et al.
Published: (2025-11-01)

EGFR polymorphisms drive lung cancer risk and survival disparities: a genotype-expression-outcome cohort study
by: Chao Zuo, et al.
Published: (2025-05-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Causal relationships between immune cell traits and HER2 subtypes in breast cancer: a Mendelian randomization study
by: Fenfen Gu, et al.
Published: (2025-08-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

The RASAL2 variant promotes aberrant RAS signaling and resistance to anti-EGFR therapy in colorectal cancer
by: Yu-Min Yeh, et al.
Published: (2025-08-01)

Successful subtotal gastrectomy and hepatectomy for HER2-positive gastric cancer with liver metastasis after trastuzumab-based chemotherapy: a case report
by: Yuki Hirase, et al.
Published: (2024-03-01)

Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+/HER2+ early breast cancer: a POETIC translational studyResearch in context
by: Milana Bergamino Sirvén, et al.
Published: (2025-08-01)

The prognostic significance of FOXP3 expression in patients with metastatic HER2-positive breast cancer
by: O.I. Vynnychenko, et al.
Published: (2024-12-01)

MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
by: V. A. Shamanin, et al.
Published: (2018-11-01)

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
by: Soo-Yeon Hwang, et al.
Published: (2025-05-01)

Editorial: EGFR-TKIs for lung cancer treatment: development, application, and side effects
by: Qinglin Shen, et al.
Published: (2025-05-01)

Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity
by: Li Luo, et al.
Published: (2025-07-01)

Efficacy and safety of trastuzumab deruxtecan in HER2-positive breast cancer patients with brain metastases after failure of pyrotinib-based therapy
by: Jinmei Zhou, et al.
Published: (2025-05-01)

EGFR tyrosine kinase inhibitor: design, synthesis, characterization, biological evaluation, and molecular docking of novel 1,3,4-oxadiazole, thio-methyl, and 1,2,3-triazole hybrids
by: Asma Khalaf Alshamari, et al.
Published: (2025-07-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

EGFR‐TKIs Induced DPP4 Drives Metabolic Reprogramming of Persister Cells in Lung Cancer
by: Yuanzhou Zhang, et al.
Published: (2025-08-01)

Multimodal prediction of tyrosine kinase inhibitors therapy outcomes in advanced EGFR-mutated NSCLC patients
by: Xiaodong Chai, et al.
Published: (2025-08-01)